Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Infliximab for Immune Checkpoint Inhibitor Associated Acute Kidney Injury
NCT07683975Phase 4Recruiting
- Sponsor
- Massachusetts General Hospital
- Start
- Sep 2026
- Primary completion
- Jan 2029
- Countries
- 1
01
Overview
A Phase 4 trial of infliximab in acute kidney injury (AKI), Acute Interstitial Nephritis (AIN), sponsored by Massachusetts General Hospital. Started Sep 2026; status: recruiting.
02
Drugs
infliximab
03
Conditions
acute kidney injury (AKI)Acute Interstitial Nephritis (AIN)
Beyond the preview
Go deeper on NCT07683975.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07683975.